ARCHIVES

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

“I’m Not Bummed Out By This” – Broder

December 22, 1994

Five Advocates Named To SWOG Committees; NCI, NASA Sign Nanotechnology Agreement.

April 21, 2000

Study: Angiopoietin-2 Levels May Predict Lenvatinib Response

October 31, 2014

In Brief: Thomas Jordan Promoted At Bristol-Myers, Markison To Succeed Him In Oncology Div.

February 28, 1992

In Brief: Ovarian Cancer Coalition Opens Office; Winchester Leads Surgical Oncologists

July 11, 1997

DCPC Concepts Approved For Tw Grants Support Contract

January 31, 1986